Company
Specgx LLC
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
11
5 still marketed
Novel approvals
2
Approvals since 2021
0
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Exalgo approved Mar 1, 2010
- Methylin approved Apr 15, 2003
- Methylin approved Dec 19, 2002
- Roxicodone approved Aug 31, 2000
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (5)
Newest FDA action first.
- Roxicodone Oxycodone Hydrochloride · 2000
- Methadose Methadone Hydrochloride · 1973
- Methylin Methylphenidate Hydrochloride · 2002
- Restoril Temazepam · 1981
- Anafranil Clomipramine Hydrochloride · 1989
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.